1. Zuberbier Т et al. European Academy of Allergy and Clinical Immunology, Global Allergy and Asthma European Network, European Dermatology Forum, World Allergy Organization Allergy 2014; 69 (7): 868–87.
2. Saini SS. Chronic spontaneous urticaria: etiology and pathogenesis. Immunol Allergy Clin North Am 2014; 34: 33–52.
3. Greaves MW. Chronic urticaria. J Allergy Clin Immunol 2000; 105: 664–72.
4. Zuberbier T, Bindslev-Jensen C, Canonica W et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006; 61: 321–31.
5. Kozel M, Sabroe R. Chronic Urticaria. Aetiology, management and current and future treatment options. Drug 2004; 64: 2516–36.
6. O`Donnell BF, Lawlor F, Simpson J et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136: 197.
7. Baiardini I, Giardini A, Pasquali M et al. Quality of life and patients’ satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58 (7): 621–3.
8. Ring J, Brockow K, Ollert M, Engst R. Antihistamines in urticaria. Clin Exp Allergy 1999; 29 (Suppl. 11): 31–7.
9. Simons FER. Prevention of acute urticaria in young children with atopic dermatitis. J Allergy Clin Immunology 2001; 107 (4): 703–6.
10. Ryhal B, Demera RS, Choenfeld Y et al. Are autoantibodies present in patients with subacute and chronic urticaria? J Invest Clin Immunol 2001; 11: 16–20.
11. Bossi F, Frossi B, Radillo O et al. Mast cells are critically involved in serum- mediated vascular leakage in chronic urticaria beyond high-affinity IgE receptor stimulation. Allergy 2011; Sep 12. Epub ahead of print.
12. Tong LJ, Balakrishnan G, Kochan JP et al. Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 1997; 99 (4): 461–5.
13. Staubach P, Onnen K, Vonend A et al. Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial. Dermatology 2006; 212 (2): 150–5.
14. Kikuchi Y, Kaplan AP. Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol 2001; 107 (6): 1056–62.
15. Spector J, Lilly S, Nemirovsky D et al. Prodromal Urticaria with Seronegative Rheumatoid Arthritis. J Clin Rheumatol 1997; 3 (4): 234–6.
16. Levine A, Dalal I, Bujanover Y. Celiac Disease Associated With Familial Chronic Urticaria and Thyroid Autoimmunity. Child Pediatrics 1999; 104 (2): e25.
17. Sabroe RA, Seed PT, Francis DM et al. Chronic idiopathic urticaria: comparison of the clinical features of patients with and without FcεRI or anti-IgE autoantibodies. J Am Acad Dermatol 1999; 40 (3): 443–50.
18. Федеральные клинические рекомендации по диагностике и лечению крапивницы. РААКИ. 2018. / Federalnye klinicheskie rekomendacii po diagnostike i lecheniyu krapivnicy. RAAKI. 2018. [in Russian]
19. The EAACI/GAZLEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014. The 2017 Revision and Update. Allergy 2018.
20. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy 2015; 45: 547–65.
21. Sánchez J, Zakzuk J, Cardona R. Prediction of the Efficacy of Antihistamines in Chronic Spontaneous Urticaria Based on Initial Suppression of the Histamine-Induced Wheal. J Investig Allergol Clin Immunol 2016; 26 (3): 177–84. DOI: 10.18176/jiaci.0039
22. Dhanya NB, Thasleem Z, Rai R, Srinivas CR. Comparative efficacy of levocetirizine, desloratidine and fexofenadine by histamine wheal suppression test. Indian J Dermatol Venereol Leprol 2008.
23. Meltzer EO, Gillman SA. Efficacy of fexofenadine versus desloratadine in suppressing histamine-induced wheal and flare. Allergy Asthma Proc 2007; 28: 67–73.
24. Астафьева Н.Г., Гамова И.В., Удовиченко Е.Н., Перфилова И.А. Левоцетиризин: современные аспекты применения при аллергических заболеваниях с точки зрения доказательной медицины. Лечащий врач. 2010; 5: 65. / Астафьева Н.Г., Гамова И.В., Удовиченко Е.Н., Перфилова И.А. Левоцетиризин: современные аспекты применения при аллергических заболеваниях с точки зрения доказательной медицины. Лечащий врач. 2010; 5: 65. [in Russian]
25. Spector SL, Shikiar R, Harding G et al. The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. Cutis 2007; 79 (2): 157–62.
26. Molimard M, Diquet B. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol 2004; 18 (4): 399–411.
27. A del Cuvillo et al. Comparative pharmacology of the H1 antihistamine. J Investig Allergol Clin Immunol 2006; 16 (Suppl. 1): 3–12.
28. Пономарева А.В., Некрасова Е.Е., Разваляева О.В. Сравнительная эффективность антиаллергической терапии хронической крапивницы у взрослых. Волгоградский науч.-мед. журн. 2012; 4 (36): 19–21. / Ponomareva A.V., Nekrasova E.E., Razvalyaeva O.V. Sravnitelnaya effektivnost antiallergicheskoj terapii hronicheskoj krapivnicy u vzroslyh. Volgogradskij nauch.-med. zhurn. 2012; 4 (36): 19–21. [in Russian]
29. Vacchiano Ch, Moore J, Rice GM, Crawley G. Fexofenadine effects on cognitive performance in aviators at ground level and simulated altitude. Aviat Space Environ Med 2008; 79 (8).
30. Tanizaki H, Nakahigashi K, Miyachi Y, Kabashima K. Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations. J Dermatolog Treat 2013; 24 (6): 477–80. DOI: 10.3109/09546634.2013.789472

________________________________________________

1. Zuberbier Т et al. European Academy of Allergy and Clinical Immunology, Global Allergy and Asthma European Network, European Dermatology Forum, World Allergy Organization Allergy 2014; 69 (7): 868–87.
2. Saini SS. Chronic spontaneous urticaria: etiology and pathogenesis. Immunol Allergy Clin North Am 2014; 34: 33–52.
3. Greaves MW. Chronic urticaria. J Allergy Clin Immunol 2000; 105: 664–72.
4. Zuberbier T, Bindslev-Jensen C, Canonica W et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006; 61: 321–31.
5. Kozel M, Sabroe R. Chronic Urticaria. Aetiology, management and current and future treatment options. Drug 2004; 64: 2516–36.
6. O`Donnell BF, Lawlor F, Simpson J et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136: 197.
7. Baiardini I, Giardini A, Pasquali M et al. Quality of life and patients’ satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58 (7): 621–3.
8. Ring J, Brockow K, Ollert M, Engst R. Antihistamines in urticaria. Clin Exp Allergy 1999; 29 (Suppl. 11): 31–7.
9. Simons FER. Prevention of acute urticaria in young children with atopic dermatitis. J Allergy Clin Immunology 2001; 107 (4): 703–6.
10. Ryhal B, Demera RS, Choenfeld Y et al. Are autoantibodies present in patients with subacute and chronic urticaria? J Invest Clin Immunol 2001; 11: 16–20.
11. Bossi F, Frossi B, Radillo O et al. Mast cells are critically involved in serum- mediated vascular leakage in chronic urticaria beyond high-affinity IgE receptor stimulation. Allergy 2011; Sep 12. Epub ahead of print.
12. Tong LJ, Balakrishnan G, Kochan JP et al. Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 1997; 99 (4): 461–5.
13. Staubach P, Onnen K, Vonend A et al. Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial. Dermatology 2006; 212 (2): 150–5.
14. Kikuchi Y, Kaplan AP. Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol 2001; 107 (6): 1056–62.
15. Spector J, Lilly S, Nemirovsky D et al. Prodromal Urticaria with Seronegative Rheumatoid Arthritis. J Clin Rheumatol 1997; 3 (4): 234–6.
16. Levine A, Dalal I, Bujanover Y. Celiac Disease Associated With Familial Chronic Urticaria and Thyroid Autoimmunity. Child Pediatrics 1999; 104 (2): e25.
17. Sabroe RA, Seed PT, Francis DM et al. Chronic idiopathic urticaria: comparison of the clinical features of patients with and without FcεRI or anti-IgE autoantibodies. J Am Acad Dermatol 1999; 40 (3): 443–50.
18. Federalnye klinicheskie rekomendacii po diagnostike i lecheniyu krapivnicy. RAAKI. 2018. 
19. The EAACI/GAZLEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014. The 2017 Revision and Update. Allergy 2018.
20. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy 2015; 45: 547–65.
21. Sánchez J, Zakzuk J, Cardona R. Prediction of the Efficacy of Antihistamines in Chronic Spontaneous Urticaria Based on Initial Suppression of the Histamine-Induced Wheal. J Investig Allergol Clin Immunol 2016; 26 (3): 177–84. DOI: 10.18176/jiaci.0039
22. Dhanya NB, Thasleem Z, Rai R, Srinivas CR. Comparative efficacy of levocetirizine, desloratidine and fexofenadine by histamine wheal suppression test. Indian J Dermatol Venereol Leprol 2008.
23. Meltzer EO, Gillman SA. Efficacy of fexofenadine versus desloratadine in suppressing histamine-induced wheal and flare. Allergy Asthma Proc 2007; 28: 67–73.
24. Астафьева Н.Г., Гамова И.В., Удовиченко Е.Н., Перфилова И.А. Левоцетиризин: современные аспекты применения при аллергических заболеваниях с точки зрения доказательной медицины. Лечащий врач. 2010; 5: 65. 
25. Spector SL, Shikiar R, Harding G et al. The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. Cutis 2007; 79 (2): 157–62.
26. Molimard M, Diquet B. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol 2004; 18 (4): 399–411.
27. A del Cuvillo et al. Comparative pharmacology of the H1 antihistamine. J Investig Allergol Clin Immunol 2006; 16 (Suppl. 1): 3–12.
28. Ponomareva A.V., Nekrasova E.E., Razvalyaeva O.V. Sravnitelnaya effektivnost antiallergicheskoj terapii hronicheskoj krapivnicy u vzroslyh. Volgogradskij nauch.-med. zhurn. 2012; 4 (36): 19–21. 
29. Vacchiano Ch, Moore J, Rice GM, Crawley G. Fexofenadine effects on cognitive performance in aviators at ground level and simulated altitude. Aviat Space Environ Med 2008; 79 (8).
30. Tanizaki H, Nakahigashi K, Miyachi Y, Kabashima K. Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations. J Dermatolog Treat 2013; 24 (6): 477–80. DOI: 10.3109/09546634.2013.789472

И.М.Корсунская*1, Е.В.Дворянкова1, З.А.Невозинская2
1. ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН. 119991, Россия, Москва, Ленинский пр-т, 
д. 38а, корп. 1;
2. ГБУЗ «Московский научно-практический центр дерматовенерологии и косметологии» Департамента здравоохранения г. Москвы. 119071, Россия, Москва, Ленинский 
пр-т, д. 17
*marykor@bk.ru

________________________________________________

I.M.Korsunskaya*1, E.V.Dvoryankova1, Z.A.Nevozinskaya2
1. Center for Theoretical Problems of Physicochemical Pharmacology of the Russian Academy of Sciences. 119991, Russian Federation, Moscow, Leninskiy pr-t, d. 38a, korp. 1;
2. Moscow Scientific and Practical Center of Dermatology and Venereology and Cosmetology of the Department of Health of Moscow. 119071, Russian Federation, Moscow, Leninskiy pr-t, d. 17
*marykor@bk.ru